Text Size

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: A meta-analysis of two phase IIIb clinical trials

Uusitalo H., Egorov E., Kaarniranta K., Astakhov Y., Ropo A.

  • 2016
  • Clinical Ophthalmology
View publication
  • Therapeutic Area


  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; Department of Ophthalmology, The Russian National Research Medical University, Moscow, Russian Federation; Department of Ophthalmology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russian Federation; Global Medical Affairs, Santen Oy, Tampere, Finland

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022